A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes
An erratum to this article was published (J Clin Endocrinol Metab, 18 Aug 2023 ↗)
Authors' conclusion
Fasting PP concentrations and the response to meal stimulation are reduced in new-onset DM associated with PDAC or CP compared with T2DM. These findings support further investigations into the use of PP concentrations to characterize pancreatogenic DM and to understand the pathophysiological role in exocrine pancreatic diseases
Study context
- Population
- Subjects with new-onset diabetes mellitus (DM) (<3 years' duration) in the setting of pancreatic ductal adenocarcinoma (PDAC), chronic pancreatitis (CP) or T2D
- Participants
- 28 / 38 / 99
- Exposure
- PDAC-DM and CP-DM vs T2DM
- PDAC-DMn = 28
- CP-DMn = 38
- T2DMn = 99reference
- Outcome
- Fold change in PP at 15 minutes after meal stimulation
- Follow-up
- 15 minutes
Methodological detailsstandardized mixed meal tolerance test, central laboratory, adjusted for age, sex and BMI
- Standardized mixed meal tolerance test
- Central laboratory
- Adjusted for age, sex and BMI
Main finding
As reported in the abstract
PDAC-DM
1.869
median
CP-DM
1.813
T2DM
3.283
PDAC-DM vs T2DM: P < 0.01 · CP-DM vs T2DM: P < 0.01
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| Fasting PP concentrationPDAC-DM vs T2DM · lower with PDAC-DM | P = 0.03 |
| Fasting PP concentrationCP-DM vs T2DM · lower with CP-DM | <0.01 |
AUC of pancreatic polypeptide (PP) concentration
- Significantly lower in both PDAC-DM and CP-DM than in T2DM regardless of the interval used; remained significant after adjustments
Original publication
A Reduced Pancreatic Polypeptide Response is Associated With New-onset Pancreatogenic Diabetes Versus Type 2 Diabetes. J Clin Endocrinol Metab. Published 21 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →